Australia Health

Prescient Therapeutics (ASX:PTX) reached its pre-specified enrolment threshold of 20 evaluable patients for the Phase 2a trial of its oncology drug PTX-100.

Telix Pharmaceuticals (ASX:TLX) appointed David Gill as chair of the board with immediate effect.

Memphasys (ASX:MEM) signed an exclusive commercialisation agreement with Denmark-based NOVIVITAE to sell and distribute its Felix System.

Racura Oncology (ASX:RAC) activated its first South Korean clinical trial site for its CPACS Phase 1 trial of RC220.

Optiscan (ASX:OIL) has initiated a US-based head and neck cancer imaging study following a research agreement with Mayo Clinic in Rochester.

CSL (ASX:CSL) has entered into agreements with the U.S. to lower domestic drug prices and expand its local manufacturing footprint.

Nanoveu (ASX:NVU) announced that Nanyang Technological University, Singapore, has been granted US Patent No. 12,651,452 B2.

Monash IVF Group (ASX:MVF) reported FY26 revenue of $269.5 million alongside an underlying net profit after tax of $16.1 million.

Austco Healthcare (ASX:AHC) recorded a 15.8% revenue increase in FY26 to reach a record $94.2 million.

Respiratory imaging business 4DMedical (ASX:4DX) reported a 77% increase in annual scan volume to 344,075 scans for FY26.

LTR Pharma (ASX:LTP) reported $19.7 million in cash with no dent for the year ended June 30.

Clinuvel Pharmaceuticals (ASX:CUV) announced its board is considering changing its holding structure to list on the Nasdaq and delist from the ASX.